Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.030
Buy
RSI(14)
48.768
Neutral
STOCH(KDJ)(9,3,3)
28.511
Sell
ATR(14)
0.231
High Vlolatility
CCI(14)
53.275
Neutral
Williams %R
84.577
Oversold
TRIX(12,20)
0.145
Sell
StochRSI(14)
7.216
Sell
Search
Aquestive Therapeutics Inc
AQSTAdd to Watchlist
4.170USD
-0.560-11.84%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
523.13MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Aquestive Therapeutics Inc
Currency: USD Updated: 2026-05-15Key Insights
Aquestive Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 74 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.89.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Aquestive Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Aquestive Therapeutics Inc Highlights
StrengthsRisks
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Growing
The company is in a growing phase, with the latest annual income totaling USD 44.55M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 44.55M.
Fairly Valued
The company’s latest PE is -6.85, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 74.94M shares, decreasing 9.08% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 10.29K shares of this stock.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
8.889
Target Price
+87.93%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Aquestive Therapeutics Inc is 6.72, ranking 133 out of 155 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 14.45M, representing a year-over-year increase of 65.67%, while its net profit experienced a year-over-year increase of 64.86%.
Score
Financials
6.36
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.84
Operational Efficiency
6.56
Growth Potential
6.72
Shareholder Returns
7.12
Aquestive Therapeutics Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Aquestive Therapeutics Inc is 6.41, ranking 121 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -6.85, which is -90.51% below the recent high of -0.65 and -592.44% above the recent low of -47.40.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 74/155
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Aquestive Therapeutics Inc is 8.44, ranking 37 out of 155 in the Pharmaceuticals industry. The average price target is 10.50, with a high of 15.00 and a low of 8.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
8.889
Target Price
+87.93%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Aquestive Therapeutics Inc
AQST
9
Amgen Inc
AMGN
38
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
33
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Aquestive Therapeutics Inc is 6.80, ranking 77 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 4.79 and the support level at 3.78, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
4.306
Sell
MA10
4.271
Sell
MA20
4.207
Sell
MA50
4.159
Buy
MA100
4.249
Sell
MA200
4.869
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Aquestive Therapeutics Inc is 5.14, ranking 74 out of 155 in the Pharmaceuticals industry. The company's beta value is 1.51. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.48
VaR
+6.87%
240-Day Maximum Drawdown
+60.61%
240-Day Volatility
+88.11%
Return
Best Daily Return
60 days
+14.53%
120 days
+38.98%
5 years
+38.98%
Worst Daily Return
60 days
-11.84%
120 days
-37.04%
5 years
-37.04%
Sharpe Ratio
60 days
+0.91
120 days
-0.23
5 years
+0.48
Risk Assessment
Maximum Drawdown
240 days
+60.61%
3 years
+63.55%
5 years
+90.11%
Return-to-Drawdown Ratio
240 days
+0.80
3 years
+0.83
5 years
+0.03
Skewness
240 days
+0.84
3 years
+0.59
5 years
+0.46
Volatility
Realised Volatility
240 days
+88.11%
5 years
+91.91%
Standardised True Range
240 days
+7.13%
5 years
+5.30%
Downside Risk-Adjusted Return
120 days
-28.55%
240 days
-28.55%
Maximum Daily Upside Volatility
60 days
+49.30%
Maximum Daily Downside Volatility
60 days
+38.99%
Liquidity
Average Turnover Rate
60 days
+1.77%
120 days
+3.34%
5 years
--
Turnover Deviation
20 days
-25.18%
60 days
-21.82%
120 days
+47.56%
Peer Comparison
Pharmaceuticals
Aquestive Therapeutics Inc
AQST
6.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
9.11 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Royalty Pharma PLC
RPRX
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Kiniksa Pharmaceuticals International PLC
KNSA
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
8.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
